SEARCH

SEARCH BY CITATION

References

  • 1
    Scadding GK, Durham SR, Mirakian R, Jones NS, Drake-Lee AB, Ryan D et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008;38:1942.
  • 2
    Naclerio RM, Meier HL, Kagey-Sobotka A, Adkinson NF Jr, Meyers DA et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983;128:597602.
  • 3
    Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193:255261.
  • 4
    Pettipher R. The roles of the prostaglandin D2 receptors DP1 and CRTH2 in promoting allergic responses. Br J Pharmacol 2008;153:S191S199.
  • 5
    Gyles SL, Xue L, Townsend ER, Wettey F, Pettipher R. A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell supernatants. Immunology 2006;119:362368.
  • 6
    Xue L, Barrow A, Pettipher R. Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells. Clin Exp Immunol 2009;156:126133.
  • 7
    Pettipher R, Vinall S, Xue L, Speight G, Townsend ER, Gazi L et al. Pharmacologic profile of OC000459, a potent, selective and orally active DP2 antagonist that inhibits mast cell-dependent activation of Th2 lymphocytes and eosinophils. J Pharmacol Exp Ther 2012;340:473482.
  • 8
    Perez-Novo CA, Holtappels G, Vinall SL, Xue L, Zhang N, Bachert C et al. CRTH2 mediates the activation of human Th2 cells in response to PGD2 released from IgE/anti-IgE treated nasal polyp tissue. Allergy 2010;65:473482.
  • 9
    Iliopoulos O, Baroody FM, Naclerio RM, Bochner BS, Kagey-Sobotka A, Lichtenstein LM. Histamine-containing cells obtained from the nose hours after antigen challenge have functional and phenotypic characteristics of basophils. J Immunol 1992;148:22232228.
  • 10
    Bacon AS, Ahluwalia P, Irani AM, Schwartz LB, Holgate ST, Church MK et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J Allergy Clin Immunol 2000;106:948954.
  • 11
    Guo CB, Liu MC, Galli SJ, Bochner BS, Kagey-Sobotka A, Lichtenstein LM. Identification of IgE-bearing cells in the late-phase response to antigen in the lung as basophils. Am J Respir Cell Mol Biol 1994;10:384390.
  • 12
    Nomiya R, Okano M, Fujiwara T, Maeda M, Kimura Y, Kino K et al. CRTH2 plays an essential role in the pathophysiology of Cry j 1-induced pollinosis in mice. J Immunol 2008;180:56805688.
  • 13
    Stebbins KJ, Broadhead AR, Correa LD, Scott JM, Truong YP, Stearns BA et al. Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol 2010;638:142149.
  • 14
    Xue L, Barrow A, Pettipher R. Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol 2009;182:75807586.
  • 15
    Horak F, Stubner P, Zieglmayer R, Kavina A, De VC, Burtin B et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001;125:7379.
  • 16
    Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol 2005;60:2431.
  • 17
    Zieglmayer UP, Horak F, Toth J, Marks B, Berger UE, Burtin B. Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus budesonide nasal spray in the management of nasal congestion in allergic rhinitis. Treat Respir Med 2005;4:283287.
  • 18
    Zieglmayer P, Zieglmayer R, Bareille P, Rousell V, Salmon E, Horak F. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin 2008;24:18331840.
  • 19
    Barnes N, Pavord I, Chuchalin A, Bell J, Hunter M, Lewis T et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 2012;42:3848.